Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06275659
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-08
First Post:
2024-02-09
Brief Title:
An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis
Sponsor:
Click Therapeutics Inc
Organization:
Click Therapeutics Inc
Study Overview
Official Title:
An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CT-100 is a platform that provides interactive software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics One class of CT-100 components are Digital Neuro-activation and Modulation DiNaMo TM components
DiNaMo components target key neural systems including but not limited to systems related to sensory- perceptual- affective- pain- attention- cognitive control social- and self- processing to optimally improve a participants health
DiNaMo components target key neural systems including but not limited to systems related to sensory- perceptual- affective- pain- attention- cognitive control social- and self- processing to optimally improve a participants health
Detailed Description:
CT-100 is a platform that provides interactive software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics One class of CT-100 components are Digital Neuro-activation and Modulation DiNaMo TM components
DiNaMo components target key neural systems including but not limited to systems related to sensory- perceptual- affective- pain- attention- cognitive control social- and self- processing to optimally improve a participants health
The purpose of the proposed study is to evaluate initial effects of the DiNaMo component on measures of undesired behavior intensity and related outcomes in a variety of conditions such as atopic dermatitis and psoriasis
DiNaMo components target key neural systems including but not limited to systems related to sensory- perceptual- affective- pain- attention- cognitive control social- and self- processing to optimally improve a participants health
The purpose of the proposed study is to evaluate initial effects of the DiNaMo component on measures of undesired behavior intensity and related outcomes in a variety of conditions such as atopic dermatitis and psoriasis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None